Matrix-Bound Vesicle Adjuvants for Low-Toxicity Vaccination

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current adjuvants like Complete Freund's Adjuvant are toxic for human vaccination and lack a suitable alternative that can induce a robust immune response.

Innovation Solution

Utilizing mammalian extracellular matrix bound vesicles (MBV) as vaccine adjuvants that do not express CD63 and CD81, administered with a vaccine antigen, to enhance immune response without toxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Complete Freund's Adjuvant is used to induce robust adaptive immunity, then immune response is improved, but toxicity and formation of granulomas and abscesses occur

Engineering Contradiction:

Improveimmune responseVSAvoidtoxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and isolates specific functional components from the complex adjuvant system. It uses matrix-bound vesicles that are separated from harmful components of traditional adjuvants, retaining only the beneficial immunostimulatory functions while eliminating toxicity. The vesicles are purified through differential centrifugation and filtration to remove contaminants.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent introduces matrix-bound vesicles as intermediary molecules that mediate the interaction between the vaccine antigen and the immune system. These vesicles serve as a bridge, delivering antigenic information to antigen-presenting cells without causing the direct tissue damage associated with traditional adjuvants like CFA.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If traditional adjuvants are used to enhance adaptive immunity, then immune response is improved, but unresolved granulomas and abscesses are induced

Engineering Contradiction:

Improveadaptive immunityVSAvoidgranulomas and abscesses

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent changes the physical and chemical parameters of the adjuvant system by using vesicular structures with specific size distributions (0.1-1000 nm) and surface properties. The matrix-bound vesicles have different biophysical characteristics compared to traditional adjuvants, allowing them to interact with immune cells through different mechanisms that do not trigger granuloma formation.

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If matrix bound vesicles are used as adjuvants, then toxicity is reduced, but immune response enhancement must be verified

Engineering Contradiction:

ImprovetoxicityVSAvoidimmune response

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent demonstrates that matrix-bound vesicles perform multiple functions simultaneously: they act as adjuvants to enhance immune response, serve as delivery vehicles for vaccine antigens, and provide structural stability to the formulation. This multi-functionality allows them to replace multiple components of traditional adjuvant systems with a single versatile element.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250375512A1Use of matrix bound vesicles (MBV) as vaccine adjuvants

Publication Date: 2025.12.11 UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

AI summary

Disclosed herein are extracellular matrix (ECM) compositions, specifically to compositions comprising matrix bound nanovesicles (MBV) and an immunogen, and the use of these compositions, e.g., in vaccination.